Dear Mr. Schierholt:

The purpose of this letter is to refer to the Ohio State Board of Pharmacy (BOP) for appropriate follow up, the U.S. Food and Drug Administration’s (FDA) concerns about compounding practices observed during an FDA inspection at a pharmacy licensed by the Ohio BOP, Buderer Drug Company, located at 38530 Chester Rd Ste 400, Avon, OH 44011-4048 (Specialty Pharmacy, License #022133300).

FDA inspected the firm from February 7, 2019, to February 14, 2019. Ohio BOP was informed of the inspection but did not accompany the FDA investigator during the inspection. A copy of a Form FDA 483 that documents our investigator’s observations from the inspection can be found at https://www.fda.gov/media/124959/download, with any nonpublic information redacted. Because we consider this inspection to be “closed” under 21 CFR 20.64(d)(3), you may request a copy of the Establishment Inspection Report (EIR) that FDA will provide to the firm, which contains additional information about our inspection. If you are a Commissioned Official or if your state agency has entered into a 21 CFR 20.88 information sharing agreement, you may be able to receive a copy of the Form FDA 483 or the EIR that includes certain nonpublic information. Alternatively, you may also choose to request a copy of the EIR directly from the firm.

During the inspection, the FDA investigators reviewed a small sample of records for products compounded by Buderer Drug Company and determined, based on this sample, that this firm appears to obtain valid prescriptions for individually-identified patients for the drug products that it compounds and distributes.

Additionally, the FDA investigator observed deviations from appropriate compounding practice standards that, if not corrected, could lead to contamination of drugs, potentially putting patients at risk. Examples of deviations observed during our inspection include:
Non-pharmaceutical grade components were used in the production of non-sterile drug products.

Buderer Drug Company committed to FDA in its response to the Form FDA 483, received March 15, 2019, to correct the deviations in the Form FDA 483 and provided documentation in support of those corrective actions. In addition, the deviations identified appear to be readily correctable.

After review of the record, FDA does not intend to take further action, at this time, with regard to the findings of this inspection. This firm apparently obtains prescriptions for identified individual patients before distributing its compounded drugs, as required by section 503A(a) of the Federal Food, Drug and Cosmetic Act, and FDA believes that the corrective actions can be appropriately overseen by the State. Therefore, FDA is referring this matter to the Ohio State BOP for follow up to ensure appropriate corrective action is taken. Please notify us if you become aware of any adverse events or product quality concerns associated with drugs made at this facility, or if you observe any practices at this facility that concern you or that could be violations of Federal law.

We look forward to continuing to work with you on the oversight of compounding pharmacies. If you have additional questions, please contact Tina Pawlowski, Compliance Officer, at 313-393-8217, or by email at ORAPHARM3_RESPONSES@fda.hhs.gov.

Sincerely,

Nicholas F. Lyons -S
Director of Compliance
Division of Pharmaceutical Quality Operations III

For

Art O. Czabaniuk
Program Division Director
Division of Pharmaceutical Quality Operations III

Cc: Matthew J. Buderer
Owner
Buderer Drug Company
26611 Dixie Highway, Suite 119
Perrysburg, OH 43551-1765